iSpecimen forges Del. COVID-19 sample alliance
iSpecimen is partnering with Doctors Pathology Services in Dover, DE, and the Delaware Health Information Network (DHIN) in Kent Acres to provide COVID-19 samples to researchers. Read More
Kiromic submits 2 IND applications to FDA
Kiromic BioPharma has submitted two investigational new drug (IND) applications to the U.S. Food and Drug Administration (FDA) for its programmed cell death 1 (PD-1) gamma-delta chimeric antigen receptor T-cell therapy. Read More
GSK licenses cancer immunotherapy from Surface Oncology
GlaxoSmithKline (GSK) has obtained an exclusive license worldwide and commercial rights to Surface Oncology's preclinical program, SRF813, an antitumor antibody. Read More
New Zealand to purchase 10.7M doses of Novavax COVID-19 vaccine
The government of New Zealand has agreed to purchase 10.7 million doses of Novavax's COVID-19 vaccine candidate, NVX-CoV2373. Read More
iMetabolic, Ligand partner on OmniAb development
iMetabolic Biopharma has announced an expansion of its partnership with Ligand Pharmaceuticals that will give it access to Ligand's OmniAb antibody discovery technology. Read More
Glycostem licenses Ghent tech to advance NK cell therapies
Glycostem Therapeutics and Ghent University have signed a license agreement for natural killer (NK) cell production technology, with the goal of producing targeted cancer treatments. Read More
Valneva begins clinical trials for inactivated, adjuvanted COVID-19 vaccine
Valneva has begun a phase I/II clinical trial to study its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. Read More
Health Canada cleared Zolgensma gene therapy for SMA
Health Canada has cleared Novartis Pharmaceuticals Canada's adeno-associated virus vector-based gene therapy product, Zolgensma, for the treatment of pediatric patients with 5q spinal muscular atrophy (SMA), a rare genetic disease and leading cause of death among infants. Read More
Mettler-Toledo announces CEO transition
Mettler-Toledo International has announced that Patrick Kaltenbach will take over as CEO in the spring. Read More
Neurogene nabs $115M in series B financing
Neurogene has completed $115 million in series B financing, which will be used to advance various aspects of the company's gene therapy programs and technology. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
